Abstract
Mucins are large glycoproteins that form a protective layer along the lumens of the organs of the gastrointestinal and reproductive tracts. Frequently in tumors of the pancreas there are changes in the structure of mucin carbohydrates and/or levels of apomucin types. Originally mucins were of interest clinically because diagnostic tests could be based on their levels in circulation. More recently mucin directed monoclonal antibodies have been used to target tumors with cytotoxic agents. There is now a considerable literature on the development of mucin-based vaccines. Both monoclonal antibodies and vaccines could be powerful tools to specifically target tumor cells in distant metastases. Gene therapy based upon the MUC1 gene promoter is being investigated to target therapeutic genes to MUC1 expressing cells. The carbohydrates of mucins on the surface of tumor cells have been reported to inhibit cells of the immune system. These carbohydrates also act as ligands during the process of tumor cell metastasis. Another approach to therapy is to block interactions between the ligands and their receptors.
Current Pharmaceutical Design
Title: Mucins in the Diagnosis and Therapy of Pancreatic Cancer
Volume: 6 Issue: 18
Author(s): Jenny J. L. Ho
Affiliation:
Abstract: Mucins are large glycoproteins that form a protective layer along the lumens of the organs of the gastrointestinal and reproductive tracts. Frequently in tumors of the pancreas there are changes in the structure of mucin carbohydrates and/or levels of apomucin types. Originally mucins were of interest clinically because diagnostic tests could be based on their levels in circulation. More recently mucin directed monoclonal antibodies have been used to target tumors with cytotoxic agents. There is now a considerable literature on the development of mucin-based vaccines. Both monoclonal antibodies and vaccines could be powerful tools to specifically target tumor cells in distant metastases. Gene therapy based upon the MUC1 gene promoter is being investigated to target therapeutic genes to MUC1 expressing cells. The carbohydrates of mucins on the surface of tumor cells have been reported to inhibit cells of the immune system. These carbohydrates also act as ligands during the process of tumor cell metastasis. Another approach to therapy is to block interactions between the ligands and their receptors.
Export Options
About this article
Cite this article as:
L. Ho J. Jenny, Mucins in the Diagnosis and Therapy of Pancreatic Cancer, Current Pharmaceutical Design 2000; 6 (18) . https://dx.doi.org/10.2174/1381612003398609
DOI https://dx.doi.org/10.2174/1381612003398609 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antibiotic Properties and Applications of Lactoferrin
Current Pharmaceutical Design Personalized Diabetes and Cancer Medicine: A Rationale for Anti-Diabetic Nutrition (Bitter Melon) in a Supportive Setting
Current Cancer Therapy Reviews Valproic Acid in the Complex Therapy of Malignant Tumors
Current Drug Targets Vascular Endothelial Growth Factor Receptors [VEGFR] as Target in Breast Cancer Treatment: Current Status in Preclinical and Clinical Studies and Future Directions
Current Topics in Medicinal Chemistry Cannabinoid Receptor Antagonists and the Metabolic Syndrome: Novel Promising Therapeutical Approaches
Mini-Reviews in Medicinal Chemistry Use of Gadoxetic Acid-enhanced MRI to Predict the Development of Postoperative Pancreatic Fistulas by Estimating the Degree of Pancreatic Fibrosis
Current Medical Imaging ATF4, an ER Stress and Hypoxia-Inducible Transcription Factor and its Potential Role in Hypoxia Tolerance and Tumorigenesis
Current Molecular Medicine Antitumor Properties of Natural Compounds and Related Molecules
Recent Patents on Anti-Cancer Drug Discovery CYP Epoxygenase Derived EETs: From Cardiovascular Protection to Human Cancer Therapy
Current Topics in Medicinal Chemistry MMP-9 Inhibitors in the Brain: Can Old Bullets Shoot New Targets?
Current Pharmaceutical Design Dihydropyrimidine Dehydrogenase Genotyping and Phenotyping for 5- Fluorouracil Dysmetabolism: Moving Towards Personalized Chemotherapy in Patients with Cancer
Current Pharmacogenomics and Personalized Medicine Regeneration of the Gastric Mucosa and its Glands from Stem Cells
Current Medicinal Chemistry The Adenosine A2b Receptor: Its Role in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Systems Biology Approaches to Pancreatic Cancer Detection, Prevention and Treatment
Current Pharmaceutical Design New Aspects of Regulatory Signaling Pathways and Novel Therapies in Pancreatic Cancer
Current Molecular Medicine Type 1 11 β-hydroxysteroid Dehydrogenase as Universal Drug Target in Metabolic Diseases?
Endocrine, Metabolic & Immune Disorders - Drug Targets A Systemic Approach to Cancer Treatment: Tumor Cell Reprogramming Focused on Endocrine-Related Cancers
Current Medicinal Chemistry Advances in the Systemic Treatment of Neuroendocrine Tumors in the Era of Molecular Therapy
Anti-Cancer Agents in Medicinal Chemistry The TGF-β 1/Foxp3 Regulatory Axis in Immune Self-Tolerance: Implications for Health and Disease
Inflammation & Allergy - Drug Targets (Discontinued) Anti-Tumor Efficacy of Pyrvinium Pamoate Nanoliposomes in an Experimental Model of Melanoma
Anti-Cancer Agents in Medicinal Chemistry